Candriam S.C.A. Protagonist Therapeutics, Inc Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Candriam S.C.A. holds 162,492 shares of PTGX stock, worth $6.39 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

162,492

Previous 273,818 40.66%

Holding current value

$6.39 Million

Previous $9.49 Million 23.03%

% of portfolio

0.04%

Previous 0.06%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$33.72 - $47.33 $3.75 Million - $5.27 Million	-111,326 Reduced 40.66%	162,492 $7.3 Million
Q2 2024 Aug 05, 2024	SELL	$24.66 - $34.8 $2.13 Million - $3 Million	-86,182 Reduced 23.94%	273,818 $9.49 Million
Q1 2024 May 03, 2024	SELL	$21.79 - $32.15 $3.86 Million - $5.69 Million	-177,000 Reduced 32.96%	360,000 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $1.31 Million - $2.18 Million	-93,000 Reduced 14.76%	537,000 $12.3 Million
Q3 2023 Nov 13, 2023	SELL	$16.68 - $23.66 $1.58 Million - $2.25 Million	-95,000 Reduced 13.1%	630,000 $10.5 Million
Q2 2023 Aug 08, 2023	BUY	$18.02 - $29.36 $1.8 Million - $2.94 Million	100,000 Added 16.0%	725,000 $20 Million
Q1 2023 May 12, 2023	BUY	$10.78 - $25.38 $6.74 Million - $15.9 Million	625,000 New	625,000 $14.4 Million
Q2 2022 Aug 03, 2022	SELL	$7.06 - $25.52 $590,540 - $2.13 Million	-83,646 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$25.57 - $44.88 $2.14 Million - $3.75 Million	83,646 New	83,646 $3.75 Million

Others Institutions Holding PTGX

# of Institutions

248

Shares Held

56.7M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account